ClinicalTrials.gg
CompletedNCT07784192Updated Oct 8, 2026

Pericapsular Nerve Group Block Versus Intrathecal Morphine for Pain After Hip Surgery

An interventional study of Morpine and Ultrasound-guided pericapsular nerve group block in Hip Arthroplasty, Total, Postoperative Pain and Hip Arthroplasty, sponsored by Selcuk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Selcuk University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 8, 2026Now CompletedNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pain, Postoperative by Selcuk University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Selcuk University.

Started
2026
with 2 others
No phase
8 of 10
4 open now
Registered
10th of 10
by date

Among the 10 studies in Pain, Postoperative by Selcuk University, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 10th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 10 studies in Pain, Postoperative by Selcuk University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pain, Postoperative by Selcuk University, or all of them as a file.
02

Study summary

Pain after hip replacement surgery is often severe and is commonly treated with opioids, which may cause nausea, vomiting, sedation, difficulty passing urine and slow breathing. This study will compare two ways of controlling pain in adults having hip surgery under spinal anesthesia. One group will receive morphine added to the spinal injection. The other group will receive an ultrasound-guided pericapsular nerve group (PENG) block, in which local anesthetic is injected near the nerves that carry pain signals from the hip joint. Participants will be assigned to one of the two groups by chance. Sixty-four adults aged 18 to 65 years will take part, with 32 in each group. Pain scores at rest and during movement, the total amount of morphine used through a patient-controlled pump, the time until the first request for extra pain medicine, the amount of additional paracetamol used, side effects such as nausea and vomiting, and complications related to the block will be compared between the groups during the first 48 hours after surgery.

Read the detailed description

Postoperative pain after total hip arthroplasty is frequently severe and limits early mobilization. Systemic opioids remain widely used but are associated with respiratory depression, sedation, urinary retention, constipation and postoperative nausea and vomiting. Intrathecal morphine added to spinal anesthesia provides prolonged analgesia but shares these opioid-related adverse effects. The pericapsular nerve group (PENG) block, first described by Giron-Arango and colleagues, targets the articular branches of the femoral, obturator and accessory obturator nerves that supply the anterior hip capsule by injecting local anesthetic into the fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Because the block spares motor fibers, it may provide effective analgesia without impairing early mobilization. Direct comparisons of the PENG block with intrathecal morphine in hip arthroplasty are limited.

This will be a prospective, randomized, controlled, open-label, single-center study conducted at Selcuk University Faculty of Medicine Hospital. Local ethics committee approval has been obtained, and written informed consent will be obtained from every participant before enrollment. Sixty-four patients aged 18 to 65 years with an American Society of Anesthesiologists physical status of I to III scheduled for unilateral hip surgery under spinal anesthesia will be allocated to one of two equal groups of 32 patients using a sealed-envelope randomization method, so that the allocation sequence is concealed from the investigator enrolling the patient. Owing to the nature of the interventions, participants, treating anesthesiologists and outcome assessors will not be blinded to group allocation. Before surgery, demographic data (age, height, weight, body mass index), comorbidities, physical status classification, type of surgery and fracture location will be recorded.

Peripheral venous access will be obtained with an 18 or 20 gauge cannula. Standard non-invasive monitoring of heart rate, systolic, diastolic and mean arterial pressures and peripheral oxygen saturation will be applied and recorded at predefined intervals from the intraoperative period until the 48th postoperative hour, with intraoperative measurements every 5 minutes. Spinal anesthesia will be performed in the sitting position under aseptic conditions at the L3-L4 or L4-L5 interspace using a 25 to 27 gauge, 90 mm Quincke spinal needle, after confirming free and clear cerebrospinal fluid flow.

Patients in Group 1 will receive 10 mg of hyperbaric bupivacaine 0.5% together with 100 micrograms of morphine hydrochloride into the intrathecal space. Patients in Group 2 will receive 10 mg of hyperbaric bupivacaine 0.5% intrathecally without morphine, followed by an ultrasound-guided PENG block on the operative side. For the block, patients will be placed supine and the area will be prepared with aseptic technique. A low-frequency (2 to 5 MHz) curvilinear ultrasound probe will be placed over the anterior inferior iliac spine and rotated approximately 45 degrees counterclockwise to align with the iliopubic eminence, visualizing the anterior inferior iliac spine, iliopubic eminence, iliopsoas tendon and femoral artery. A 21 gauge, 80 to 100 mm insulated, echogenic short-bevel needle will be advanced in-plane from lateral to medial until the tip lies in the plane between the iliopubic eminence and the iliopsoas tendon. After negative aspiration for blood and sonographic confirmation of needle position, 20 mL of 0.5% bupivacaine will be injected. Adequacy of the neuraxial block will be confirmed before surgery begins.

Postoperative analgesia will be provided with intravenous patient-controlled analgesia using morphine, programmed to deliver a 1 mg bolus dose with a 10-minute lockout interval and no background infusion. Intravenous paracetamol 1000 mg will be administered on demand as rescue analgesia, without exceeding a total daily dose of 4000 mg. Pain intensity at rest and on movement will be assessed with a Visual Analog Scale at the 1st, 3rd, 6th, 12th, 24th and 48th postoperative hours. Analgesic consumption, patient-controlled analgesia demand and delivery ratios, time to first rescue analgesic request, the incidence of nausea and vomiting, and block-related complications such as arterial puncture, hematoma, paresthesia during injection and signs of local anesthetic systemic toxicity will be recorded during the 0 to 1, 1 to 3, 3 to 6, 6 to 12, 12 to 24 and 24 to 48 hour intervals. Total analgesic consumption over 48 hours will also be recorded. Before every regional block, the expiry date and availability of 20% lipid emulsion will be checked, and the anesthesia machine, circuit leak test, defibrillator and emergency drug trolley will be verified.

The primary outcome will be cumulative morphine consumption during the first 24 postoperative hours. Secondary outcomes will include cumulative morphine consumption over 48 hours, pain scores at rest and on movement at each assessment point, time to first patient-controlled analgesia demand, total paracetamol consumption, incidence of postoperative nausea and vomiting and block-related complications.

03

Conditions studied

  • Hip Arthroplasty, Total
  • Postoperative Pain
  • Hip Arthroplasty
  • Analgesia
  • Hip Fractures (ICD-10 72.01-72.2)

Keywords

  • Arthroplasty
  • Hip Analgesia
  • Nerve Block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years
  • physical status I, II or III
  • Scheduled for unilateral hip surgery under spinal anesthesia, including hip fracture surgery and hip replacement surgery
  • Able to understand and use the Visual Analog Scale and the patient-controlled analgesia device
  • Written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Known allergy or to local anesthetics, morphine or paracetamol
  • Any to spinal anesthesia, including coagulopathy, ongoing anticoagulant therapy, thrombocytopenia, infection at the puncture site, or raised intracranial pressure
  • Local infection or previous surgery at the pericapsular nerve group block site
  • Chronic opioid use or history of substance use disorder
  • Chronic pain requiring regular analgesic treatment before surgery
  • Cognitive impairment, psychiatric disorder or communication difficulty preventing use of the pain scales
  • Pre-existing neurological deficit in the operative lower limb
  • above 40 kg/m²
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Intrathecal Morphine Group

    Patients receive spinal anesthesia with 10 mg hyperbaric bupivacaine 0.5% plus 100 micrograms of preservative-free morphine into the intrathecal space.

    Drug: Morpine · Drug: Bupivacaine

  • Experimental
    PENG Block Group

    Patients receive spinal anesthesia with 10 mg hyperbaric bupivacaine 0.5% alone, followed by an ultrasound-guided pericapsular nerve group (PENG) block on the operated side with 20 mL of 0.5% bupivacaine.

    Procedure: Ultrasound-guided pericapsular nerve group block · Drug: Bupivacaine

Interventions

  • DrugMorphine hydrochlorideStudies of Morphine hydrochlorideMorphine hydrochloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Preservative-free morphine hydrochloride 100 micrograms will be added to 10 mg of hyperbaric bupivacaine 0.5% and administered into the intrathecal space at the L3-L4 or L4-L5 interspace as part of spinal anesthesia.

    Also known as: Morphine hydrochloride, ntrathecal morphine

  • ProcedureUltrasound-guided pericapsular nerve group block

    After spinal anesthesia, an ultrasound-guided pericapsular nerve group block will be performed on the operative side. A 21 gauge, 80 to 100 mm echogenic needle will be advanced in-plane from lateral to medial into the fascial plane between the iliopubic eminence and the iliopsoas tendon, and 20 mL of bupivacaine 0.5% will be injected after negative aspiration.

  • Hyperbaric bupivacaine 0.5%, 10 mg, will be administered intrathecally in both groups as the spinal anesthetic. In the PENG block group, an additional 20 mL of bupivacaine 0.5% will be used for the block.

    Also known as: Bupivacaine hydrochloride

06

What researchers measure

Primary outcomes

  1. Cumulative intravenous morphine consumption at 24 hours

    Total amount of morphine, in milligrams, delivered by the intravenous patient-controlled analgesia device during the first 24 postoperative hours, recorded from the device log. Lower values indicate lower opioid requirement.

    Time frame: 0 to 24 hours after surgery

Secondary outcomes

  1. Cumulative intravenous morphine consumption at 48 hours

    Total amount of morphine, in milligrams, delivered by the intravenous patient-controlled analgesia device during the first 48 postoperative hours, recorded from the device log. Lower values indicate lower opioid requirement.

    Time frame: 0 to 48 hours after surgery

  2. Pain intensity at rest measured with the Visual Analog Scale

    Pain at rest is rated by the participant on a 0 to 100 mm Visual Analog Scale, where 0 mm indicates no pain and 100 mm indicates the worst imaginable pain. Lower scores indicate less pain.

    Time frame: 1, 3, 6, 12, 24 and 48 hours after surgery

  3. Pain intensity on movement measured with the Visual Analog Scale

    Pain during passive flexion of the operated hip is rated by the participant on a 0 to 100 mm Visual Analog Scale, where 0 mm indicates no pain and 100 mm indicates the worst imaginable pain. Lower scores indicate less pain.

    Time frame: 1, 3, 6, 12, 24 and 48 hours after surgery

  4. Time to first patient-controlled analgesia demand

    Time in minutes from the end of the intrathecal injection to the first demand recorded by the patient-controlled analgesia device. Longer times indicate a longer duration of analgesia.

    Time frame: 0 to 48 hours after surgery

  5. Cumulative paracetamol consumption

    Total amount of intravenous paracetamol, in milligrams, administered on demand as rescue analgesia during the first 48 postoperative hours, with a maximum of 4000 mg per day. Lower values indicate lower rescue analgesic requirement.

    Time frame: 0 to 48 hours after surgery

  6. Number of participants with postoperative nausea and vomiting

    Number of participants experiencing nausea, vomiting or both, and the number requiring antiemetic treatment, recorded at each assessment interval.

    Time frame: 0 to 48 hours after surgery

  7. Number of participants with block-related complications

    Number of participants with arterial puncture, hematoma, paresthesia during injection, quadriceps weakness, or clinical signs of local anesthetic systemic toxicity such as perioral numbness, tinnitus, seizure or arrhythmia.

    Time frame: 0 to 48 hours after surgery

07

Study locations

1 site
  • Selcuk University Hospital
    Konya, Selcuklu, Turkey (Türkiye)
08

References and documents

Publications

  • Liu SS, Wu CL. The effect of analgesic technique on postoperative patient-reported outcomes including analgesia: a systematic review. Anesth Analg. 2007 Sep;105(3):789-808. doi: 10.1213/01.ane.0000278089.16848.1e. PubMed 17717242 ↗
  • Giron-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847. PubMed 30063657 ↗
  • Short AJ, Barnett JJG, Gofeld M, Baig E, Lam K, Agur AMR, Peng PWH. Anatomic Study of Innervation of the Anterior Hip Capsule: Implication for Image-Guided Intervention. Reg Anesth Pain Med. 2018 Feb;43(2):186-192. doi: 10.1097/AAP.0000000000000701. PubMed 29140962 ↗
  • Pivec R, Issa K, Naziri Q, Kapadia BH, Bonutti PM, Mont MA. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop. 2014 Jun;38(6):1159-65. doi: 10.1007/s00264-014-2298-x. Epub 2014 Feb 27. PubMed 24573819 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2026 to primary completion in Oct 2026, 1 month.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 25, 2026
StartActual
Aug 24, 2026
Primary completionActual
Oct 4, 2026was Sep 2026
CompletionActual
Oct 7, 2026was Sep 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 5, 2026 · changed Oct 8, 2026
Primary completion
Sep 18, 2026→Oct 4, 2026
Oct 5, 2026
Study completion
Sep 25, 2026→Oct 7, 2026
Oct 5, 2026
Show all 2 updates
  1. Oct 8, 2026
    Active, not recruiting→Completed
    + 1 other change: date precision
  2. Oct 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 18, 2026→Oct 4, 2026
    Study completion Sep 25, 2026→Oct 7, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07784192
Lead sponsor
Selcuk University
Responsible party
NARGIZ MAMMADOVA (Principal Investigator, Selcuk University) — Principal investigator
First posted
Aug 25, 2026
Start date
Aug 24, 2026
Primary completion
Oct 4, 2026
Completion
Oct 7, 2026
Last update
Oct 8, 2026

Study contacts

Inci KARA
study director · Selcuk University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion